Differential Effects of Vasopressin and Oxytocin on Attention Control

Sponsor

University of Electronic Science and Technology of China (Other)

Overall Status

Completed

CT.gov ID

NCT04715737

Collaborator

(none)

160

Enrollment

Location

Arms

36.4

Actual Duration (Months)

4.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) and oxytocin (24IU) have differential effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: Vasopressin Drug: Oxytocin Drug: Placebo	N/A

Detailed Description

Previous studies have demonstrated intranasal vasopressin and oxytocin's divergent effects on social behavior and emotion processing such as empathy and negative emotion processing, however, it remains unclear whether vasopressin and oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored intranasal vasopressin and oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare vasopressin and oxytocin's effects on attention control to social emotional stimuli. To this end data from subjects who underwent intranasal oxytocin administration (n = 33; NCT03486925) will be compared with data from subjects who underwent intranasal vasopressin or placebo administration (n = 39, or 45 respectively; NCT04493554). To further control for non-treatment related factors the intranasal placebo groups from the previous studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.

Study Design

Study Type:

Interventional

Actual Enrollment :

160 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking designBetween-subject randomized placebo-controlled double-blind pharmacological eye-tracking design

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Basic Science

Official Title:

The Differential Effects of Intranasal Vasopressin and Oxytocin on Attention Control

Actual Study Start Date :

Dec 19, 2017

Actual Primary Completion Date :

Jan 1, 2021

Actual Study Completion Date :

Jan 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Vasopressin Vasopressin (20IU) intranasally	Drug: Vasopressin Administration of vasopressin (20IU) intranasally
Experimental: Oxytocin Oxytocin (24IU) intranasally	Drug: Oxytocin Administration of oxytocin (24IU) intranasally
Placebo Comparator: Placebo Placebo intranasally	Drug: Placebo Administration of placebo intranasally

Arm

Intervention/Treatment

Experimental: Vasopressin

Vasopressin (20IU) intranasally

Drug: Vasopressin

Administration of vasopressin (20IU) intranasally

Experimental: Oxytocin

Oxytocin (24IU) intranasally

Drug: Oxytocin

Administration of oxytocin (24IU) intranasally

Placebo Comparator: Placebo

Placebo intranasally

Drug: Placebo

Administration of placebo intranasally

Outcome Measures

Primary Outcome Measures

Differential effects of intranasal vasopressin and oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli [Time Frame: 45 minutes - 100 minutes after treatment]
Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Differential effects of intranasal vasopressin and oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli [Time Frame: 45 minutes - 100 minutes after treatment]
Comparison between social-specific error rates of saccade/antisaccade between the vasopressin, oxytocin and placebo treatment conditions

Secondary Outcome Measures

Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions [Time Frame: 45 minutes - 100 minutes after treatment]
Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Emotion-specific effects of vasopressin and oxytocin administration on saccade/antisaccade error rates for the separate facial emotions [Time Frame: 45 minutes - 100 minutes after treatment]
Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin, oxytocin and placebo treatment conditions

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 30 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Male, healthy participants
Non smokers

Exclusion Criteria:

Previous or current medical, psychiatric, neurological disorder
Regular medication
Use of any psychoactive substances in the 24 hours before experiment

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Electronic Science and Technology of China (UESTC)	Sichuan	Chengdu	China	611731

Sponsors and Collaborators

University of Electronic Science and Technology of China

Investigators

Principal Investigator: Keith Kendrick, PhD, University of Electronic Science and Technology of China (UESTC)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Keith Kendrick, Professor, University of Electronic Science and Technology of China

ClinicalTrials.gov Identifier:

NCT04715737

Other Study ID Numbers:

UESTC-neuSCAN-76

First Posted:

Jan 20, 2021

Last Update Posted:

Jan 22, 2021

Last Verified:

Jan 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Keith Kendrick, Professor, University of Electronic Science and Technology of China

Additional relevant MeSH terms:

Vasopressins

Arginine Vasopressin

Oxytocin

Study Results

No Results Posted as of Jan 22, 2021